Cancer DiscoveryCancer BiologyPeer-reviewed journal article
AI-powered Deep Visual Proteomics reveals critical molecular transitions in pancreatic cancer precursors
Jimin MiniD, Lisa SchweizeriD, Gijs ZonderlandiD, Benson Chellakkan SelvanesaniD, Julie H. ThomseniD, Lukas OldenburgiD, Seong-Woo BaeiD, Bongjun KimiD, Sharia D. HernandeziD, Gabriela JeziD, Vincent BernardiD, Benjamin J. SwansoniD, Kelsey A. KluteiD, Huamin WangiD, Thomas C. CaffreyiD, Paul M. GrandgenettiD, Michael Anthony HollingsworthiD, Ishani UmmatiD, Maximilian T. StraussiD, Andreas MundiD, Anirban MaitraiD
Abstract
Pancreatic ductal adenocarcinoma (PDAC) evolves through non-invasive precursor lesions, yet its earliest molecular events remain unclear. We established the first spatially resolved proteomic atlas of these lesions using Deep Visual Proteomics (DVP). AI-driven computational pathology classified normal ducts, acinar-ductal metaplasia (ADM), and pancreatic intraepithelial neoplasia (PanIN) from cancer-free organ donors (incidental, "iPanINs") and PDAC patients (cancer-associated, "cPanINs"). Laser microdissection of 96 discrete regions containing as few as 100 phenotypically matched cells and ultrasensitive mass spectrometry quantified a total of 8,512 proteins from formalin-fixed tissues. Distinct molecular signatures stratifying cPanINs from iPanINs, and remarkably, many cancer-associated proteins already marked histologically normal epithelium. Four core programs - stress adaptation, immune engagement, metabolic reprogramming, mitochondrial dysfunction - emerged early and intensified during progression. By integrating DVP with AI-guided tissue annotation, we demonstrate that molecular reprogramming precedes histological transformation, creating opportunities for earlier detection and interception of a near-uniformly lethal cancer. SignificanceOur spatially-resolved proteomics atlas uncovers distinct molecular signatures in pancreatic cancer adjacent precursor lesions, clearly diverging from those in incidental, cancer-free pancreatic lesions. Our deep proteomics dataset offers a valuable resource for identifying novel biomarkers and therapeutic targets, informed by the earliest cancer-associated molecular events in archival pancreatic tissues.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- approach: deep learning
- Citations
- 7
- FWCI
- 20.51
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High-Sensitive Spatial Proteomics for Pancreatic Cancer Progression Analysis
Jongmin Jacob Woo, Zhenyu Sun, … Hui Zhang·Analytical ChemistryPeer-reviewed·Feb 18, 2026
- Targeted and Explorative Profiling of Kallikrein Proteases and Global Proteome Biology of Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Normal Pancreas Highlights Disease-Specific Proteome Remodelling
J. Werner, P. Bernhard, … O. Schilling·bioRxiv·Nov 28, 2022
- Form Follows Function: A New Paradigm of Pancreatic Cancer Progression
William Gasper, Giada Pontecorvi, … Matteo Ligorio·bioRxiv·Aug 12, 2025
- DETECTION OF INCIPIENT PANCREATIC CANCER WITH NOVEL TUMOR-SPECIFIC ANTIBODIES IN MOUSE MODELS
T. E. Oni, C. Bautista, … D. A. Tuveson·bioRxiv·Sep 10, 2020
- PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides
C. Saillard, F. Delecourt, … J. Cros·bioRxiv·Jan 4, 2022
- Integrative analysis of genomic and transcriptomic data informs precancer progression in the pancreas
Kathleen Noller, Jiaying Lai, … Elana Judith Fertig·bioRxiv·Nov 3, 2025